Table 2 |
|||
|
Secondary parameters to be included in WARN Pharmacokinetic Database, if available. |
|||
| Patient characteristics |
Antimalarial |
Methodology |
Pharmacokinetic parameters |
|
|
|||
| Height |
Directly Observed Therapy (DOT) [1] |
Method for separating free drug |
Primary parameters: Absorption rate constant (Ka); Elimination Rate constant (Ke),
Volume of distribution; Clearance rate. |
| Vomiting |
Batch number & Expiry Date |
Sample handling |
Secondary parameters: Cmax, tmax, elimination half-life; |
| Diarrhoea |
Method of Administration [2] |
Total vs free drug |
|
| Baseline parasite density |
Co-administration [3] |
Metabolites |
|
| Haematocrit, Bilirubin, Creatinine, Albumin (alpha1 glycoprotein, lipoprotein) |
|||
| Ethnicity |
|||
|
|
|||
|
Footnotes to Table 2 DOT: All doses supervised; First dose supervised; Unsupervised. 2. Administration: Whole tablets; Divided tablets; Crushed tablets. 3. Co-administration: Water; Fat content; Sugar water; Concomitant medication |
|||
|
Barnes et al. Malaria Journal 2007 6:122 doi:10.1186/1475-2875-6-122 |
|||
